Home > > > Molybdenum 99 Market Size to Reach USD 5.56 Billion by 2033, Driven by Nuclear Imaging Demand and Ex

Molybdenum 99 Market Size to Reach USD 5.56 Billion by 2033, Driven by Nuclear Imaging Demand and Ex

Author : Sameer Straits2 | Published On : 28 Apr 2026

The global Molybdenum 99 Market is witnessing steady growth as healthcare systems increasingly depend on nuclear medicine for early disease detection, functional imaging, and precision diagnostics. Molybdenum-99 is a critical medical radioisotope used to generate Technetium-99m, one of the most widely used isotopes in diagnostic imaging procedures worldwide.

According to the latest analysis by Straits Research, the global molybdenum 99 market was valued at USD 3.92 billion in 2024 and is projected to grow from USD 4.07 billion in 2025 to USD 5.56 billion by 2033, registering a CAGR of 3.96% during the forecast period.

Get Free Sample Report & Key Insights: https://straitsresearch.com/report/global-molybdenum-99-market/request-sample

Market Overview

Molybdenum-99 is a radioactive isotope primarily used in the production of Technetium-99m generators for nuclear diagnostic procedures. It plays a vital role in imaging scans related to cardiology, oncology, bone disorders, kidney function, and neurological conditions.

The market is benefiting from rising global healthcare demand, increasing incidence of chronic diseases, aging populations, and growing adoption of non-invasive imaging technologies. Hospitals and diagnostic centers rely heavily on nuclear imaging tools for accurate and early-stage disease detection.

Additionally, ongoing advancements in isotope production methods, supply chain resilience, and non-highly enriched uranium production technologies are helping improve long-term market sustainability.

Market Drivers

Growing Demand for Diagnostic Imaging
Increasing use of nuclear scans in cardiology, cancer detection, and organ function analysis is supporting demand for molybdenum-99.

Rising Burden of Chronic Diseases
Higher rates of cardiovascular disease, cancer, and age-related illnesses are driving the need for accurate diagnostic procedures.

Expansion of Nuclear Medicine Infrastructure
Hospitals and imaging centers worldwide are investing in modern nuclear medicine facilities and radiopharmacy capabilities.

Shift Toward Safer Production Methods
The transition from highly enriched uranium to non-highly enriched uranium production is strengthening supply diversification and regulatory acceptance.

Unlock Full Market Report: https://straitsresearch.com/report/global-molybdenum-99-market

Market Challenges

Despite favorable growth prospects, the market faces challenges such as short isotope half-life, complex logistics, limited global production facilities, regulatory compliance, reactor dependency, and supply disruptions caused by maintenance shutdowns or geopolitical factors.

Market Segmentation

By Product Type

  • Production by Non-Highly Enriched Uranium: Increasingly preferred due to safety, non-proliferation goals, and regulatory support.
  • Production by Highly Enriched Uranium: Legacy production route still used in selected facilities.

By Industry

  • Scientific Research: Used in isotope development, radiochemistry, and advanced research applications.
  • Medical: Largest segment driven by diagnostic imaging demand.

By Isotopic Application

  • Gamma Camera: Used in conventional nuclear imaging procedures.
  • SPECT: Strong demand for single-photon emission computed tomography systems offering advanced imaging detail.

By End User

  • Research Institutes: Academic and scientific centers focused on isotope innovation.
  • Hospitals and Diagnostic Centers: Major end users performing routine nuclear medicine scans.

Regional Insights

North America
North America remains a leading market due to advanced healthcare infrastructure, high imaging procedure volumes, and continued investment in isotope production.

Europe
Europe demonstrates stable growth supported by strong public healthcare systems, research institutions, and established nuclear medicine networks.

Asia-Pacific
Asia-Pacific is expected to witness notable growth due to expanding healthcare access, rising chronic disease prevalence, and increasing diagnostic capacity.

Latin America
Regional demand is supported by modernization of hospitals and broader access to advanced imaging technologies.

Middle East and Africa
Growing healthcare investments and improving diagnostic services are creating gradual market opportunities.

Competitive Landscape

The molybdenum 99 market is specialized and strategically important, with players focusing on reliable isotope supply, production innovation, and strategic healthcare partnerships. Key companies covered in the report include:

  • Curium Company
  • Eckert & Ziegler Holding Company
  • Shine Medical Technologies
  • NTP Radioisotopes SOC Ltd.
  • North Star Medical Radioisotopes LLC
  • JSC Isotope
  • ANSTO
  • Lantheus Medical Imaging Inc.
  • IRE ELIT
  • Niowave Inc.

Future Outlook

The future of the molybdenum 99 market remains promising as nuclear medicine continues to expand globally. Increasing diagnostic demand, safer isotope production technologies, and healthcare modernization are expected to support steady market growth through 2033.